Artivion, Inc. (NYSE:AORT – Get Free Report) SVP Jean F. Holloway sold 3,167 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $26.55, for a total transaction of $84,083.85. Following the sale, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at $4,299,294.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Artivion Stock Up 1.5 %
Shares of NYSE AORT opened at $26.86 on Friday. The stock has a fifty day moving average price of $26.00 and a 200 day moving average price of $22.92. The company has a current ratio of 6.04, a quick ratio of 4.26 and a debt-to-equity ratio of 1.07. Artivion, Inc. has a 12-month low of $12.16 and a 12-month high of $29.24. The company has a market cap of $1.12 billion, a P/E ratio of -111.92 and a beta of 1.75.
Artivion (NYSE:AORT – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.04. The company had revenue of $98.02 million during the quarter, compared to the consensus estimate of $97.70 million. Artivion had a positive return on equity of 3.64% and a negative net margin of 2.61%. Research analysts anticipate that Artivion, Inc. will post 0.24 EPS for the current fiscal year.
Institutional Trading of Artivion
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on AORT shares. Stifel Nicolaus lifted their target price on Artivion from $25.00 to $28.00 and gave the company a “buy” rating in a report on Friday, August 9th. Lake Street Capital lifted their price objective on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Needham & Company LLC reissued a “buy” rating and set a $30.00 target price on shares of Artivion in a research report on Friday, August 9th. Finally, Oppenheimer raised their price target on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, August 9th.
Read Our Latest Analysis on Artivion
Artivion Company Profile
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
See Also
- Five stocks we like better than Artivion
- 3 Tickers Leading a Meme Stock Revival
- Applied Digital’s Stock Recovery: Analysts Forecast Strong Upside
- Manufacturing Stocks Investing
- Ollie’s Stock Goes On Sale: It’s Time To Back Up The Truck
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.